Li Jinsong, Liu Quan, Zheng Zhikun, Li Shoukang
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Transl Cancer Res. 2020 Oct;9(10):5893-5899. doi: 10.21037/tcr-20-951.
Thymoma is the most common tumor within the anterior mediastinum though it is still a rare tumor disease. Surgery is considered to be one of the most important treatment methods for it, while radiotherapy and platinum-based chemotherapy are also in use. Based on the Surveillance, Epidemiology and End Results (SEER) database, we conducted our research and determined the value of operation in the treatment of thymoma.
In total, 1,587 patients with thymoma were selected out from the database. We grouped them according to type and stage of thymoma. We used cox-regression analysis to selected meaningful factors. Kaplan-Meier method was used for survival analysis.
The mean survival times of patients with type A, B, C thymoma were 130.79, 123.81, 77.18 months orderly. Among all 1,587 patients, the mean survival time of those treated with surgery was 124.92 months, while it was 65.03 months for those without surgery treatment (P<0.05). Within each group of patients with the same kind of and same stage thymoma, who got surgical treatment had a longer survival period (P<0.05).
Type c thymoma had the worst prognosis. Patients who received surgical treatment had longer survival time. And it didn't matter what type or what stage of thymoma.
胸腺瘤是前纵隔最常见的肿瘤，尽管它仍然是一种罕见的肿瘤疾病。手术被认为是其最重要的治疗方法之一，同时放疗和铂类化疗也在使用。基于监测、流行病学和最终结果（SEER）数据库，我们开展了研究并确定了手术在胸腺瘤治疗中的价值。
从数据库中总共选取了1587例胸腺瘤患者。我们根据胸腺瘤的类型和分期对他们进行分组。我们使用cox回归分析来选择有意义的因素。采用Kaplan-Meier方法进行生存分析。
A型、B型、C型胸腺瘤患者的平均生存时间依次为130.79、123.81、77.18个月。在所有1587例患者中，接受手术治疗的患者平均生存时间为124.92个月，而未接受手术治疗的患者平均生存时间为65.03个月（P<0.05）。在每一组相同类型和相同分期的胸腺瘤患者中，接受手术治疗的患者生存期更长（P<0.05）。
C型胸腺瘤预后最差。接受手术治疗的患者生存时间更长。且无论胸腺瘤的类型或分期如何。
